Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation

Four men with amyotrophic lateral sclerosis (ALS) were treated with 200 mg of intramuscular testosterone weekly. Endocrine evaluation, using a gonadotropin-releasing hormone infusion test, indicated the expected degree of suppression of pituitary luteinizing hormone and follicle-stimulating hormone production. These data suggest that testosterone's (androgen) interaction with its receptors in the hypothalamic-pituitary axis is normal in patients with ALS.